Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer

New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer
Study:
  • Multicenter, nonrandomized phase II study
  • HER2-mutated, advanced NSCLC with ≥ one previous line including platinums
  • Pertuzumab+trastuzumab+docetaxel (n=45)
Efficacy:
  • ORR: 29%, SD: 58%
  • mPFS: 6.8 mos, mOS: 17.6 mos
  • 5 year OS: 20.5% vs 6.5%
Safety:
  • Grade >=3 AEs: 64%
  • Neutropenia 33%, diarrhea 13%, anemia 9%

J Clin Oncol. 2022 Mar 1;40(7):719-728.

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

https://doi.org/10.1200/jco.21.01455

Reviewed by Hasan Cagri Yildirim, MD on Mar 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More